Dendritic cell-based immunotherapy (DCBI) showed promising results in patients with pleural mesothelioma . The primary aim of this trial was to determine feasibility of adjuvant DCBI after CRS-HIPEC . Median progression-free survival (PFS) was 12 months (IQR 5–23) Median overall survival was not reached .